Detransitioner Chloe Cole: I was their experiment | The Riley Gaines Show
Riley Gaines recently spoke with Chloe Cole, a notable figure in the anti-transition movement, about her journey involving puberty blockers, testosterone, and surgeries at a young age. Chloe expressed her belief that minors are incapable of giving informed consent for such impactful medical decisions. She recounted her experiences seeking help from the very medical professionals who treated her and explained her reasons for filing a lawsuit against Kaiser Permanente. The discussion also touched on family planning within gender medicine, the current climate for free speech on campuses, the backlash women encounter for advocating biological truths, and Chloe’s changing Christian faith. Topics like detransition, gender ideology, medical ethics, parental rights, faith, and cultural conflicts over truth and womanhood were all covered.
Meanwhile, Rep. Diana Hershberger (R-Tenn.), who has a pharmacy background, is pushing for legislation that mandates health insurance providers to cover both the detransition and any side effects associated with transgender procedures.
Hershberger voiced concerns that many existing insurance plans leave individuals looking to reverse their gender reassignment with few options. She stated, “It’s outrageous that health insurance can cover gender denial surgery but not the recovery care needed to address the harm patients cause. It’s not a fair trade for patients who want to restore healthy functioning.”
When confronted with a straightforward question about whether men can give birth, medical school deans appeared perplexed, labeling the inquiry as “ridiculous.”
Although the bill, named the Truth in Reporting Act, might struggle to gain traction in the Senate due to opposition from Democrats, it highlights growing legislative worries over the increasing number of individuals regretful of their gender reassignment treatments and the challenges they face when addressing related side effects.
If the bill passes, insurance companies that offer “gender-denial surgery” would also need to cover products and services required for mitigating complications and adverse effects arising from these procedures. This requirement would be implemented regardless of existing state or local regulations.
The proposed law could take effect on January 1, 2027, and has attracted twelve co-sponsors, including Georgia’s Representative Buddy Carter, who previously chaired the Energy, Commerce, and Health subcommittee.
Hershberger’s proposal aims to amend three federal laws regarding private health insurance and establish consistent federal coverage standards—specifically, the Public Health Service Act, employer-sponsored health plans, and group health plans. Furthermore, it would prevent insurers from modifying copays, deductibles, or enforcing treatment limits.
Last year, Texas Governor Greg Abbott approved similar legislation to address comparable concerns locally.
Texas Senator Brian Hughes, supporter of Senate Bill 1257, commented on the necessity of such measures, emphasizing that many patients require significant medical attention to manage or reverse effects of prior treatments, often without insurance backing them. This ends up creating overwhelming out-of-pocket costs and introduces various health risks, from hormonal imbalances to surgical complications and mental distress.
The National Library of Medicine has noted that determining the number of detransitions is complex, as factors such as discontinuing hormone therapy, canceling surgeries, or changing legal documents can signal the beginning of the detransition journey.
The aim of Hershberger’s bill is to simplify this by broadly encompassing adverse effects.
“Once reality sets in, we should never abandon patients who have undergone harmful, life-altering medical interventions,” Hershberger remarked.
“As a pharmacist, I have seen insurance companies find every excuse to avoid paying for treatments that patients need. My truth in coverage law restores equity, promotes transparency, and ensures that patients don’t have to cover costs for treatments that should be insured.”
At this time, it remains uncertain when the House will vote on Hershberger’s proposal.
